Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + nab-paclitaxel + dostarlimab
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a **combination regimen** composed of carboplatin (a platinum-based chemotherapeutic), nab-paclitaxel (a nanoparticle albumin-bound formulation of paclitaxel, used for its antineoplastic effects), and dostarlimab (a humanized monoclonal antibody targeting PD-1, marketed as Jemperli). - **Carboplatin** is a cytotoxic agent that forms DNA crosslinks, thereby inhibiting DNA synthesis and function. - **Nab-paclitaxel** stabilizes microtubules and prevents their depolymerization, thereby blocking cell division. - **Dostarlimab** is a programmed cell death protein 1 (PD-1) immune checkpoint inhibitor; it blocks the PD-1 receptor on T cells, enhancing immune-mediated anti-tumor activity. This combination is used as a systemic therapy in certain solid tumors, notably in endometrial cancer. - The combination (especially carboplatin + paclitaxel + dostarlimab) is approved for advanced or recurrent endometrial cancer, enhancing overall survival over chemotherapy alone[1][3][4][6].
- Brand names
- Jemperli (for dostarlimab)Abraxane (for nab-paclitaxel)
- Other names
- carboplatin + nab-paclitaxel + dostarlimab
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on carboplatin + nab-paclitaxel + dostarlimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + nab-paclitaxel + dostarlimab.